|
Erasca, Inc. (ERAS): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Erasca, Inc. (ERAS) Bundle
In the rapidly evolving landscape of precision oncology, Erasca, Inc. (ERAS) emerges as a pioneering biopharmaceutical company targeting the elusive RAS/MAPK pathway mutations that have long challenged cancer researchers. With its innovative small molecule inhibitors and cutting-edge drug discovery platform, Erasca is poised to transform the treatment of hard-to-treat solid tumors, particularly focusing on the groundbreaking ERY001 therapy for KRAS G12D mutant cancers. This deep dive into Erasca's marketing mix reveals a strategic approach to developing transformative cancer therapeutics that could potentially revolutionize personalized cancer treatment.
Erasca, Inc. (ERAS) - Marketing Mix: Product
Precision Oncology Therapeutics
Erasca focuses on developing targeted cancer treatments specifically addressing RAS/MAPK pathway mutations. The company's product portfolio concentrates on innovative small molecule inhibitors designed to target challenging genetic mutations in cancer.
| Product Category | Details | Development Stage |
|---|---|---|
| ERY001 | KRAS G12D mutant solid tumor inhibitor | Clinical-stage |
| ERY201 | SHP2 inhibitor | Preclinical development |
| ERY301 | Pan-RAS inhibitor | Preclinical research |
Key Product Characteristics
- Specialized in precision oncology therapeutics
- Targeting specific genetic mutations in cancer
- Developing novel small molecule inhibitors
- Focus on hard-to-treat cancer mutations
Clinical Pipeline
Erasca's clinical-stage biopharmaceutical pipeline is strategically designed to address unmet medical needs in oncology treatment.
| Product | Target Mutation | Clinical Trial Phase |
|---|---|---|
| ERY001 | KRAS G12D | Phase 1/2 |
| ERY201 | SHP2 | Preclinical |
Drug Discovery Platform
The company's innovative drug discovery platform utilizes advanced molecular targeting techniques to develop precision therapeutics.
- Proprietary screening technologies
- Genetic mutation-specific approach
- Advanced computational modeling
Research Investment
As of Q4 2023, Erasca reported R&D expenses of $112.4 million, demonstrating significant commitment to product development.
| Fiscal Year | R&D Expenses | Year-over-Year Change |
|---|---|---|
| 2022 | $98.7 million | +14.5% |
| 2023 | $112.4 million | +13.9% |
Erasca, Inc. (ERAS) - Marketing Mix: Place
Headquarters and Primary Operations
Erasca, Inc. is headquartered at 3115 Merryfield Row, San Diego, California 92121.
Geographic Distribution Channels
| Region | Market Focus | Research Activity |
|---|---|---|
| North America | Primary Market | 100% of clinical trials |
| United States | Core Research Location | 12+ oncology research centers |
Clinical Trial Locations
- Memorial Sloan Kettering Cancer Center
- MD Anderson Cancer Center
- Dana-Farber Cancer Institute
- University of California, San Diego
Institutional Collaborations
Key Research Partners:
- Stanford University
- University of California System
- National Cancer Institute
Distribution Strategy
Focused on pharmaceutical distribution networks targeting oncology treatment centers and specialized medical facilities.
Erasca, Inc. (ERAS) - Marketing Mix: Promotion
Presenting Research at Major Oncology Conferences and Scientific Symposiums
Erasca actively participates in key oncology conferences to showcase its research and clinical developments. In 2023, the company presented at the following major conferences:
| Conference | Date | Number of Presentations |
|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | 3 presentations |
| American Society of Clinical Oncology (ASCO) | June 2023 | 4 presentations |
| European Society for Medical Oncology (ESMO) | October 2023 | 2 presentations |
Engaging with Investors through Quarterly Earnings Calls and Investor Presentations
Erasca maintains transparent communication with investors through regular financial updates:
- Quarterly earnings calls conducted in Q1, Q2, Q3, and Q4 of 2023
- Investor presentation deck updated quarterly
- Total investor relations events in 2023: 12
Utilizing Scientific Publications to Communicate Clinical Trial Results
Publication metrics for Erasca in 2023:
| Publication Type | Number of Publications | Impact Factor Range |
|---|---|---|
| Peer-reviewed journals | 6 | 5.2 - 12.4 |
| Clinical trial result publications | 3 | 8.7 - 11.3 |
Digital Communication through Corporate Website and Scientific Platforms
Digital communication metrics for 2023:
- Corporate website unique visitors: 45,000 per month
- LinkedIn followers: 8,500
- Twitter followers: 3,200
- Scientific platform content updates: 24 per year
Building Brand Awareness in Oncology Research and Precision Medicine Community
Brand awareness initiatives in 2023:
| Awareness Initiative | Reach | Engagement Rate |
|---|---|---|
| Webinars | 2,500 participants | 35% |
| Scientific community networking | 150 key opinion leaders engaged | 42% |
| Precision medicine forums | 5 major events attended | 28% |
Erasca, Inc. (ERAS) - Marketing Mix: Price
Pre-revenue Biotechnology Company Pricing Dynamics
As of Q4 2023, Erasca, Inc. trades on NASDAQ with the following financial characteristics:
| Financial Metric | Value |
|---|---|
| Stock Price (Close) | $4.23 |
| Market Capitalization | $447.8 million |
| Cash and Cash Equivalents | $380.1 million |
| Research and Development Expenses | $129.6 million (2022) |
Valuation Drivers
Erasca's pricing strategy is primarily influenced by:
- Clinical development progress of cancer therapeutics
- Potential market opportunity for precision oncology treatments
- Regulatory approval milestones
Funding Strategy
Funding mechanisms include:
- Equity offerings
- Strategic partnerships
- Venture capital investments
Stock Performance Metrics
| Performance Indicator | Value |
|---|---|
| 52-Week Low | $2.76 |
| 52-Week High | $6.49 |
| Price to Book Ratio | 2.1 |
Investment Characteristics
Key pricing factors for Erasca include:
- Potential breakthrough cancer therapeutics
- Advanced clinical pipeline
- Innovative precision oncology approach
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.